Distigmine bromide 5mg/5ml oral solution
Requires a prescription from a doctor or prescriber
Distigmine is a parasympathomimetic agent with a longer duration of action and enhanced drug accumulation compared to [DB00545] and [DB01400].
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Distigmine
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Distigmine
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
WHO defined daily dose (DDD)
5 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 2 · 1966–2023
Showing the 50 most relevant studies, sorted by most relevant.
Reactions Weekly, 2023
Manabu Fujinawa, Hitoshi Iino, Akira Yamazaki, et al.
Nihon Naika Gakkai Zasshi, 2023
Masayoshi Tada, Nobuya Fujita, Maiko Umeda, et al.
PubMed, 2004
- Tamsulosin
- Urinary Bladder, Neurogenic
- Cholinesterase Inhibitors
Makoto Onodera
PubMed, 2008
- Acetylcholine
- Acute Disease
- Autonomic Nervous System Diseases
Sreekanth Reddy Obireddy, M. C. S. Subha, T. Jithendra, et al.
Journal of Drug Delivery and Therapeutics, 2019
This paper reports the fabrication of gelatin/karaya gum microspheres by emulsion crosslinking method for controlled release of distigmine bromide. The microspheres were crosslinked with the help of glutaraldehyde and used for controlled oral delivery of distigmine bromide. The obtained microspheres were characterized by Fourier transform infrared spectroscopy, differential scanning calorimetry, X-ray diffraction and scanning electron microscopy. Drug release kinetics of the microspheres is investigated in simulated intestinal fluid pH 7.4 at 37oC. Results illustrated that microspheres was influenced by the pH of test mediums, which might be suitable for intestinal drug delivery. The drug release kinetics was analyzed by evaluating the release data using different kinetic models. Keywords: Karaya Gum, Gelatin, microspheres, drug delivery.
Abstract licence: CC BY-NC 4.0
Keisuke Obara, Yurina Kobayashi, Daisuke Chino, et al.
Pharmacology, 2016
- Urinary Bladder
- Cholinesterase Inhibitors
- Electric Stimulation
Keisuke Obara, D. Chino, Yoshio Tanaka
Biological & pharmaceutical bulletin, 2017
- Acetylcholinesterase
- Cholinesterase Inhibitors
- Pyridinium Compounds
Keisuke Obara, Yurina Kobayashi, Daisuke Chino, et al.
European Journal of Pharmacology, 2017
- Electric Stimulation
- Urinary Bladder
- Guinea Pigs
Keisuke Obara, Tsukasa Ogawa, Daisuke Chino, et al.
Biological & Pharmaceutical Bulletin, 2017
- Acetylcholine
- Cholinesterase Inhibitors
- Guinea Pigs
Kazuki Kobayashi, Hiroshi Sekiguchi, Nobuhiro Sato, et al.
PubMed, 2016
- Cholinesterase Inhibitors
- Cholinesterases
- Intestinal Absorption
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Investigational
Major interactions
None known
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 292 interactions
ATC N07AA03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Distigmine
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q3277473), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.